Tags

Type your tag names separated by a space and hit enter

Sativex for the management of multiple sclerosis symptoms.

Abstract

Sativex (R) is a cannabis-based pharmaceutical product containing delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio, delivered in an oromucosal (mouth) spray. It has been approved as adjunctive treatment for neuropathic pain in patients with multiple sclerosis (MS). It is being investigated for the management of other MS symptoms, such as spasticity. THC:CBD spray is regulated as a narcotic. Five randomized controlled trials (RCTs) compared the benefits and harms of THC:CBD spray with placebo. A total of 368 patients with various neurological conditions (including MS) were recruited. In some trials, THC:CBD spray significantly reduced neuropathic pain, spasticity, muscle spasms and sleep disturbances. The most common adverse events (AEs) reported in trials were dizziness, sleepiness, fatigue, feeling of intoxication and a bad taste. Long-term safety and the potential for dependence, abuse, misuse and diversion are unknown.

Links

  • clinical trials
  • Authors

    Source

    MeSH

    Administration, Oral
    Administration, Sublingual
    Aerosols
    Analgesics
    Canada
    Cannabidiol
    Dronabinol
    Drug Approval
    Humans
    Multiple Sclerosis
    Muscle Spasticity
    Pain
    Phytotherapy
    Plant Extracts
    Randomized Controlled Trials as Topic
    Sleep Wake Disorders
    Tremor
    United Kingdom

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    16317825

    Citation

    Perras C, . "Sativex for the Management of Multiple Sclerosis Symptoms." Issues in Emerging Health Technologies, 2005, pp. 1-4.
    Perras C . Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol. 2005.
    Perras C, . (2005). Sativex for the management of multiple sclerosis symptoms. Issues in Emerging Health Technologies, (72), pp. 1-4.
    Perras C . Sativex for the Management of Multiple Sclerosis Symptoms. Issues Emerg Health Technol. 2005;(72)1-4. PubMed PMID: 16317825.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Sativex for the management of multiple sclerosis symptoms. A1 - Perras C,, PY - 2005/12/2/pubmed PY - 2005/12/15/medline PY - 2005/12/2/entrez SP - 1 EP - 4 JF - Issues in emerging health technologies JO - Issues Emerg Health Technol IS - 72 N2 - Sativex (R) is a cannabis-based pharmaceutical product containing delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio, delivered in an oromucosal (mouth) spray. It has been approved as adjunctive treatment for neuropathic pain in patients with multiple sclerosis (MS). It is being investigated for the management of other MS symptoms, such as spasticity. THC:CBD spray is regulated as a narcotic. Five randomized controlled trials (RCTs) compared the benefits and harms of THC:CBD spray with placebo. A total of 368 patients with various neurological conditions (including MS) were recruited. In some trials, THC:CBD spray significantly reduced neuropathic pain, spasticity, muscle spasms and sleep disturbances. The most common adverse events (AEs) reported in trials were dizziness, sleepiness, fatigue, feeling of intoxication and a bad taste. Long-term safety and the potential for dependence, abuse, misuse and diversion are unknown. SN - 1488-6316 UR - https://www.unboundmedicine.com/medline/citation/16317825/Sativex_for_the_management_of_multiple_sclerosis_symptoms_ L2 - https://ClinicalTrials.gov/search/term=16317825 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -